Collegium Pharmaceutical Inc (COLL)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $786.83M
Last updated: Nov 17, 2026 at 4:10 PM ET
Collegium Pharmaceutical Inc (COLL) Statistics
Collegium Pharmaceutical (COLL) has a market cap of $786.83M and an enterprise value of $1.74B. Its net debt of $950.01M equals 120.74% of its market cap. Its trailing P/E of 3.7x is below its 5-year median of 6.2x.
Total Valuation
Enterprise value is 120.74% above the market cap, as debt exceeds cash.
| Market Cap | $786.83M |
|---|---|
| Enterprise Value | $1.74B |
| Latest price (Nov 17, 2026) | $25.55 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.0x and 2.7x. Its year-end P/E ranged from 4.4x to 82.3x from 2019 to 2025.
| P/E Ratio | 3.7x |
|---|---|
| Forward P/E | 3.3x |
| P/S Ratio | 1.0x |
| Forward P/S | 0.9x |
| P/B Ratio | 2.7x |
| P/FCF Ratio | 2.4x |
| P/OCF Ratio | 2.3x |
| PEG Ratio | 0.5 |
Enterprise Valuation
Counting debt and cash, the company is valued at 4.9x EBITDA and 5.2x free cash flow.
| EV / Earnings | 45.5x |
|---|---|
| EV / Sales | 2.1x |
| EV / EBITDA | 4.9x |
| EV / EBIT | 14.0x |
| EV / FCF | 5.2x |
Price Statistics
The stock is down 44.43% over 52 weeks and trades 10.51% above its 50-day average.
| Beta (1Y) | 0.15 |
|---|---|
| 52-Week Change | -44.43% |
| 1-Month Change | +11.04% |
| 3-Month Change | -11.10% |
| 6-Month Change | -24.00% |
| 5-Year Change | +21.24% |
| 10-Year Change | +58.98% |
| Total Return (1Y) | -44.43% |
| Total Return (3Y CAGR) | +0.55% |
| Total Return (5Y CAGR) | +6.05% |
| Return vs SPY (1Y) | -55.21% |
| Max Drawdown (1Y) | -56.80% |
| Max Drawdown (3Y) | -56.80% |
| Sharpe Ratio (1Y) | -1.35 |
| Correlation with SPY (1Y) | 0.05 |
| 50-Day Average | $23.12 |
| 200-Day Average | $31.95 |
| 52-Week Range | $21.43 to $50.79 |
| RSI (14 Days) | 65.7 |
| Average Volume (20 Days) | 617.33K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.01x current liabilities, and total debt is 3.69x shareholder equity.
| Current Ratio | 1.01x |
|---|---|
| Quick Ratio | 0.87x |
| Debt / Equity | 3.69x |
| Debt / EBITDA | 3.03x |
| Debt / FCF | 3.26x |
| Interest Coverage | 1.34x |
Returns and Efficiency
Return on invested capital is 8.08% over the last 12 months, against a 5-year average of 7.98%.
| Return on Equity (ROE) | 12.88% |
|---|---|
| Return on Assets (ROA) | 1.82% |
| Return on Invested Capital (ROIC) | 8.08% |
| Return on Capital Employed (ROCE) | 8.31% |
| ROE (5Y Average) | 19.63% |
| ROA (5Y Average) | 4.07% |
| ROIC (5Y Average) | 7.98% |
| Asset Turnover | 0.44x |
| Inventory Turnover | 3.31x |
| Receivables Turnover | 2.74x |
| Cash Conversion Cycle | 233 days |
Taxes
Income tax took 9.45% of pretax income over the last 12 months.
| Income Tax (TTM) | $3.98M |
|---|---|
| Effective Tax Rate | 9.45% |
Scores
COLL has an Altman Z-Score of 0.81, in the distress zone below 1.81, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 0.81 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $815.19M over the last 12 months is up 7.68% from the 12 months before.
| Revenue | $815.19M |
|---|---|
| Revenue Growth (YoY) | +7.68% |
| Gross Profit | $481.33M |
| Operating Income | $124.07M |
| Pretax Income | $42.15M |
| Net Income | $38.17M |
| EBITDA | $360.89M |
| EBIT | $124.07M |
| Reported EPS (TTM) | $6.89 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 14.12% of the $2.10B in total assets.
| Cash and Equivalents | $144.80M |
|---|---|
| Total Debt | $1.09B |
| Net Debt | $950.01M |
| Net Debt Per Share | $29.94 |
| Working Capital | $8.67M |
| Shareholder Equity | $296.44M |
| Book Value Per Share | $9.34 |
| Tangible Book Value | -$1.03B |
| Total Assets | $2.10B |
| Total Liabilities | $1.80B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.73M of capital spending, operating cash flow left $336.29M of free cash flow.
| Operating Cash Flow | $338.02M |
|---|---|
| Capital Expenditures | $1.73M |
| Free Cash Flow | $336.29M |
| FCF Per Share | $10.33 |
| Depreciation and Amortization | $236.82M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 15.22%, against a 5-year average of 18.59%.
| Gross Margin | 59.05% |
|---|---|
| Operating Margin | 15.22% |
| Pretax Margin | 5.17% |
| Net Margin | 4.68% |
| EBITDA Margin | 44.27% |
| EBIT Margin | 15.22% |
| FCF Margin | 41.25% |
| Gross Margin (5Y Average) | 55.24% |
| Operating Margin (5Y Average) | 18.59% |
| Net Margin (5Y Average) | 9.59% |
Growth
Revenue grew 18.94% a year over 3 years, and EPS 32.87% a year.
| Revenue Growth (3Y CAGR) | +18.94% |
|---|---|
| Revenue Growth (5Y CAGR) | +20.28% |
| EPS Growth (3Y CAGR) | +32.87% |
| EPS Growth (5Y CAGR) | +26.38% |
| FCF Growth (3Y CAGR) | +38.76% |
| FCF Growth (5Y CAGR) | +29.95% |
| Operating Income Growth (3Y CAGR) | +75.35% |
| Book Value Per Share Growth (2Y CAGR) | +27.47% |
Dividends and Yields
COLL does not pay a dividend. Its free cash flow yield is 41.48%.
| Earnings Yield | 27.03% |
|---|---|
| FCF Yield | 41.48% |
| Buyback Yield | 5.94% |
| Shareholder Yield | 5.94% |
Peer Position
Against 10 similar companies, COLL has the lowest P/E.
P/E RatioPeer median 11.8x
P/S RatioPeer median 2.0x
ROICPeer median 7.85%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +15.08%
| P/E Ratio | 3.7x vs 11.8x median |
|---|---|
| P/S Ratio | 1.0x vs 2.0x median |
| ROIC | 8.08% vs 7.85% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +7.68% vs +15.08% median |
Analyst Forecast
Consensus estimates put revenue growth at 4.21% and EPS growth at 0.13% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +4.21% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +0.13% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About COLL
What is COLL's market cap?
Collegium Pharmaceutical has a market cap of $786.83M. Its enterprise value, which adds debt and subtracts cash, is $1.74B.
What is COLL's P/E ratio?
Collegium Pharmaceutical has a trailing P/E ratio of 3.7x and a forward P/E of 3.3x.
How many shares of COLL are outstanding?
Collegium Pharmaceutical has 31.73M shares outstanding. The count is up 0.51% from a year earlier.
Does COLL pay a dividend?
No. Collegium Pharmaceutical does not pay a dividend.
How much debt does COLL have?
Collegium Pharmaceutical has $1.09B of total debt and $144.80M of cash and equivalents, a net debt position of $950.01M.
COLL pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors